CDK4/6抑制剂在早期乳腺癌辅助治疗应用的热点问题OA

Hormone receptor positive/human epidermal growth factor receptor 2 negative(HR+/HER2-)breast cancer is the predominant molecular subtype.However,even after completion of standard adjuvant endocrine therapy,patients of this subtype continue to face a persistent risk of late recurrence.Cyclin-dependent kinase 4/6(CDK4/6)inhibitors precisely target dysregulated cell-cycle progression.They have been proved to significantly reduce the risk of recurrence in high-risk early-stage patients in the adjuvant setting,thereby reshaping the treatment landscape of HR+/HER2-early breast cancer.This review systematically summarized the key evidence supporting adjuvant CDK4/6 inhibitor therapy,critically analyzed current controversies in clinical practice,outlined major recommendations from international and national guidelines,discussed strategies for individualized treatment optimization,and provided perspectives on future research directions.These insights may help inform the standardized and precise use of CDK4/6 inhibitors for patients of early breast cancer.